Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Adaptive Regulation of Osteopontin Production by Dendritic Cells Through the Bidirectional Interaction With Mesenchymal Stromal Cells.

Scutera S, Salvi V, Lorenzi L, Piersigilli G, Lonardi S, Alotto D, Casarin S, Castagnoli C, Dander E, D'Amico G, Sozzani S, Musso T.

Front Immunol. 2018 Jun 1;9:1207. doi: 10.3389/fimmu.2018.01207. eCollection 2018.

2.

Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print]

PMID:
29897402
3.

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print]

PMID:
29873679
4.

Author Correction: The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients.

Rampazzo E, Del Bianco P, Bertorelle R, Boso C, Perin A, Spiro G, Bergamo F, Belluco C, Buonadonna A, Palazzari E, Lonardi S, De Paoli A, Pucciarelli S, De Rossi A.

Br J Cancer. 2018 May 21. doi: 10.1038/s41416-018-0067-0. [Epub ahead of print]

PMID:
29780160
5.

slan+ monocytes and macrophages mediate CD20-dependent B cell lymphoma elimination via ADCC and ADCP.

Vermi W, Micheletti A, Finotti G, Tecchio C, Calzetti F, Costa S, Bugatti M, Calza S, Agostinelli C, Pileri S, Balzarini P, Tucci A, Rossi G, Furlani L, Todeschini G, Zamò A, Facchetti F, Lorenzi L, Lonardi S, Cassatella MA.

Cancer Res. 2018 May 10. pii: canres.2344.2017. doi: 10.1158/0008-5472.CAN-17-2344. [Epub ahead of print]

PMID:
29748373
6.

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.

Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassineti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A.

Oncologist. 2018 May 8. pii: theoncologist.2017-0573. doi: 10.1634/theoncologist.2017-0573. [Epub ahead of print]

PMID:
29739893
7.

A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It.

Tamassia N, Arruda-Silva F, Calzetti F, Lonardi S, Gasperini S, Gardiman E, Bianchetto-Aguilera F, Gatta LB, Girolomoni G, Mantovani A, Vermi W, Cassatella MA.

Front Immunol. 2018 Apr 17;9:795. doi: 10.3389/fimmu.2018.00795. eCollection 2018.

8.

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G.

Front Pharmacol. 2018 Apr 13;9:367. doi: 10.3389/fphar.2018.00367. eCollection 2018.

9.

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.

Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators.

J Clin Oncol. 2018 May 20;36(15):1478-1485. doi: 10.1200/JCO.2017.76.2187. Epub 2018 Apr 5.

PMID:
29620994
10.

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ.

Clin Colorectal Cancer. 2018 Jun;17(2):e395-e414. doi: 10.1016/j.clcc.2018.02.010. Epub 2018 Feb 27.

PMID:
29606345
11.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F.

Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5.

PMID:
29582224
12.

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F.

Br J Cancer. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13.

PMID:
29531324
13.

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.

Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ.

PLoS One. 2018 Mar 9;13(3):e0193640. doi: 10.1371/journal.pone.0193640. eCollection 2018.

14.

Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.

Giurisato E, Xu Q, Lonardi S, Telfer B, Russo I, Pearson A, Finegan KG, Wang W, Wang J, Gray NS, Vermi W, Xia Z, Tournier C.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):E2801-E2810. doi: 10.1073/pnas.1707929115. Epub 2018 Mar 5.

15.

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

Di Desidero T, Orlandi P, Fioravanti A, Cremolini C, Loupakis F, Marmorino F, Antoniotti C, Masi G, Lonardi S, Bergamo F, Zagonel V, Falcone A, Bocci G.

Invest New Drugs. 2018 Feb 27. doi: 10.1007/s10637-018-0579-8. [Epub ahead of print]

PMID:
29488048
16.

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R.

Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

17.

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

Cremolini C, Antoniotti C, Lonardi S, Aprile G, Bergamo F, Masi G, Grande R, Tonini G, Mescoli C, Cardellino GG, Coltelli L, Salvatore L, Corsi DC, Lupi C, Gemma D, Ronzoni M, Dell'Aquila E, Marmorino F, Di Fabio F, Mancini ML, Marcucci L, Fontanini G, Zagonel V, Boni L, Falcone A.

JAMA Oncol. 2018 Apr 1;4(4):529-536. doi: 10.1001/jamaoncol.2017.5314.

PMID:
29450468
18.

Cutaneous infiltration of plasmacytoid dendritic cells and T regulatory cells in skin lesions of polymorphic light eruption.

Rossi MT, Arisi M, Lonardi S, Lorenzi L, Ungari M, Serana F, Fusano M, Moggio E, Calzavara-Pinton PG, Venturini M.

J Eur Acad Dermatol Venereol. 2018 Jun;32(6):985-991. doi: 10.1111/jdv.14866. Epub 2018 Feb 27.

PMID:
29430717
19.

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S.

BMC Cancer. 2018 Jan 25;18(1):98. doi: 10.1186/s12885-018-4001-x.

20.

A multi-parent advanced generation inter-cross (MAGIC) population for genetic analysis and improvement of cowpea (Vigna unguiculata L. Walp.).

Huynh BL, Ehlers JD, Huang BE, Muñoz-Amatriaín M, Lonardi S, Santos JRP, Ndeve A, Batieno BJ, Boukar O, Cisse N, Drabo I, Fatokun C, Kusi F, Agyare RY, Guo YN, Herniter I, Lo S, Wanamaker SI, Xu S, Close TJ, Roberts PA.

Plant J. 2018 Mar;93(6):1129-1142. doi: 10.1111/tpj.13827. Epub 2018 Feb 24.

PMID:
29356213
21.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
22.

The role of tumor angiogenesis as a therapeutic target in colorectal cancer.

Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F.

Expert Rev Anticancer Ther. 2018 Mar;18(3):251-266. doi: 10.1080/14737140.2018.1428092. Epub 2018 Jan 19.

PMID:
29338550
23.

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, Santini D.

Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.

PMID:
29324972
24.

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S.

ESMO Open. 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017.

25.

Helicobacter pylori Affects the Antigen Presentation Activity of Macrophages Modulating the Expression of the Immune Receptor CD300E through miR-4270.

Pagliari M, Munari F, Toffoletto M, Lonardi S, Chemello F, Codolo G, Millino C, Della Bella C, Pacchioni B, Vermi W, Fassan M, de Bernard M, Cagnin S.

Front Immunol. 2017 Oct 12;8:1288. doi: 10.3389/fimmu.2017.01288. eCollection 2017.

26.

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.

Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M.

Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

27.

Potential contribution of tumor-associated slan+ cells as anti-CSF-1R targets in human carcinoma.

Lonardi S, Licini S, Micheletti A, Finotti G, Vermi W, Cassatella MA.

J Leukoc Biol. 2018 Mar;103(3):559-564. doi: 10.1189/jlb.1MA0717-300R. Epub 2017 Dec 28.

PMID:
28951423
28.

Comprehensive benchmarking and ensemble approaches for metagenomic classifiers.

McIntyre ABR, Ounit R, Afshinnekoo E, Prill RJ, Hénaff E, Alexander N, Minot SS, Danko D, Foox J, Ahsanuddin S, Tighe S, Hasan NA, Subramanian P, Moffat K, Levy S, Lonardi S, Greenfield N, Colwell RR, Rosen GL, Mason CE.

Genome Biol. 2017 Sep 21;18(1):182. doi: 10.1186/s13059-017-1299-7.

29.

Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.

Aliberti C, Carandina R, Lonardi S, Dadduzio V, Vitale A, Gringeri E, Zanus G, Cillo U.

J Vasc Interv Radiol. 2017 Nov;28(11):1495-1502. doi: 10.1016/j.jvir.2017.07.020. Epub 2017 Sep 18.

PMID:
28927662
30.

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.

Giampieri R, Puzzoni M, Daniele B, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Pella N, Zampino MG, Sozzi P, Germano D, Zagonel V, Codecà C, Libertini M, Labianca R, Cascinu S; Italian Group for the Study of Gastrointestinal Cancer (GISCAD), Scartozzi M.

Br J Cancer. 2017 Oct 10;117(8):1099-1104. doi: 10.1038/bjc.2017.234. Epub 2017 Sep 19.

PMID:
28926529
31.

New perspectives for TAS-102: TASK successful?

Loupakis F, Lonardi S.

Lancet Oncol. 2017 Sep;18(9):1139-1141. doi: 10.1016/S1470-2045(17)30574-0. Epub 2017 Jul 28. No abstract available.

PMID:
28760400
32.

Immunotherapy in Gastrointestinal Cancers.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S.

Biomed Res Int. 2017;2017:4346576. doi: 10.1155/2017/4346576. Epub 2017 Jul 3. Review.

33.

Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study.

Barina A, De Paoli A, Delrio P, Guerrieri M, Muratore A, Bianco F, Vespa D, Asteria C, Morpurgo E, Restivo A, Coco C, Pace U, Belluco C, Aschele C, Lonardi S, Valentini V, Mantello G, Maretto I, Del Bianco P, Perin A, Pucciarelli S.

Tech Coloproctol. 2017 Aug;21(8):633-640. doi: 10.1007/s10151-017-1665-1. Epub 2017 Jul 28.

PMID:
28755256
34.

Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.

Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F.

Expert Opin Biol Ther. 2017 Oct;17(10):1297-1308. doi: 10.1080/14712598.2017.1356815. Epub 2017 Jul 28. Review.

PMID:
28752777
35.

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.

Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J.

Cancer Chemother Pharmacol. 2017 Sep;80(3):599-608. doi: 10.1007/s00280-017-3380-z. Epub 2017 Jul 25.

36.

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.

Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators.

Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20.

PMID:
28735067
37.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.

PMID:
28734759
38.

BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling.

Galuppini F, Pennelli G, Loupakis F, Lanza C, Vianello L, Sacchi D, Mescoli C, Salmaso R, Agostini M, Lonardi S, Farinati F, Rugge M, Fassan M.

Histopathology. 2017 Dec;71(6):1008-1011. doi: 10.1111/his.13315. Epub 2017 Sep 28. No abstract available.

PMID:
28722262
39.

Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients *.

Bergamo F, Lonardi S, Salmaso B, Lacognata C, Battaglin F, Cavallin F, Saadeh L, Murgioni S, Caruso A, Aliberti C, Zagonel V, Castoro C, Scarpa M.

Acta Oncol. 2018 Mar;57(3):412-419. doi: 10.1080/0284186X.2017.1351038. Epub 2017 Jul 15.

PMID:
28712314
40.

Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells.

Costa S, Marini O, Bevilacqua D, DeFranco AL, Hou B, Lonardi S, Vermi W, Rodegher P, Panato A, Tagliaro F, Lowell CA, Cassatella MA, Girolomoni G, Scapini P.

J Leukoc Biol. 2017 Sep;102(3):791-803. doi: 10.1189/jlb.3MA0217-054RR. Epub 2017 Jun 22.

PMID:
28642279
41.

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest.

BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

42.

The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.

Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, Perucho L, Petrocelli V, Haake A, Lee AK, Bugatti M, Paul U, Van Anken E, Pasqualucci L, Rabadan R, Siebert R, Kempa S, Ponzoni M, Facchetti F, Rajewsky K, Casola S.

Nature. 2017 Jun 8;546(7657):302-306. doi: 10.1038/nature22353. Epub 2017 May 31.

PMID:
28562582
43.

A comparative evaluation of genome assembly reconciliation tools.

Alhakami H, Mirebrahim H, Lonardi S.

Genome Biol. 2017 May 18;18(1):93. doi: 10.1186/s13059-017-1213-3.

44.

Construction of a map-based reference genome sequence for barley, Hordeum vulgare L.

Beier S, Himmelbach A, Colmsee C, Zhang XQ, Barrero RA, Zhang Q, Li L, Bayer M, Bolser D, Taudien S, Groth M, Felder M, Hastie A, Šimková H, Staňková H, Vrána J, Chan S, Muñoz-Amatriaín M, Ounit R, Wanamaker S, Schmutzer T, Aliyeva-Schnorr L, Grasso S, Tanskanen J, Sampath D, Heavens D, Cao S, Chapman B, Dai F, Han Y, Li H, Li X, Lin C, McCooke JK, Tan C, Wang S, Yin S, Zhou G, Poland JA, Bellgard MI, Houben A, Doležel J, Ayling S, Lonardi S, Langridge P, Muehlbauer GJ, Kersey P, Clark MD, Caccamo M, Schulman AH, Platzer M, Close TJ, Hansson M, Zhang G, Braumann I, Li C, Waugh R, Scholz U, Stein N, Mascher M.

Sci Data. 2017 Apr 27;4:170044. doi: 10.1038/sdata.2017.44.

45.

A chromosome conformation capture ordered sequence of the barley genome.

Mascher M, Gundlach H, Himmelbach A, Beier S, Twardziok SO, Wicker T, Radchuk V, Dockter C, Hedley PE, Russell J, Bayer M, Ramsay L, Liu H, Haberer G, Zhang XQ, Zhang Q, Barrero RA, Li L, Taudien S, Groth M, Felder M, Hastie A, Šimková H, Staňková H, Vrána J, Chan S, Muñoz-Amatriaín M, Ounit R, Wanamaker S, Bolser D, Colmsee C, Schmutzer T, Aliyeva-Schnorr L, Grasso S, Tanskanen J, Chailyan A, Sampath D, Heavens D, Clissold L, Cao S, Chapman B, Dai F, Han Y, Li H, Li X, Lin C, McCooke JK, Tan C, Wang P, Wang S, Yin S, Zhou G, Poland JA, Bellgard MI, Borisjuk L, Houben A, Doležel J, Ayling S, Lonardi S, Kersey P, Langridge P, Muehlbauer GJ, Clark MD, Caccamo M, Schulman AH, Mayer KFX, Platzer M, Close TJ, Scholz U, Hansson M, Zhang G, Braumann I, Spannagl M, Li C, Waugh R, Stein N.

Nature. 2017 Apr 26;544(7651):427-433. doi: 10.1038/nature22043.

PMID:
28447635
46.

QoL is a cool tool.

Procaccio L, Lonardi S, Loupakis F, Di Maio M.

Ann Oncol. 2017 Aug 1;28(8):2032-2033. doi: 10.1093/annonc/mdx199. No abstract available.

PMID:
28430888
47.

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ.

Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26.

PMID:
28347919
48.

IL-21 May Promote Granzyme B-Dependent NK/Plasmacytoid Dendritic Cell Functional Interaction in Cutaneous Lupus Erythematosus.

Salvi V, Vermi W, Cavani A, Lonardi S, Carbone T, Facchetti F, Bosisio D, Sozzani S.

J Invest Dermatol. 2017 Jul;137(7):1493-1500. doi: 10.1016/j.jid.2017.03.016. Epub 2017 Mar 23.

PMID:
28344062
49.

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.

Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators.

Ann Oncol. 2017 Dec 1;28(12):3110. doi: 10.1093/annonc/mdx021. No abstract available.

PMID:
28327986
50.

An untreatable dyspnoea: more defendants under investigation.

Ferrarese A, Bergamo F, Calabrese F, Girolami B, Iovino S, Lonardi S, Nannini N, Vio S, Zola E, Vianello A, Baggio G.

Intern Emerg Med. 2017 Mar;12(2):199-205. doi: 10.1007/s11739-017-1632-x. Epub 2017 Feb 14. No abstract available.

PMID:
28197811

Supplemental Content

Loading ...
Support Center